SCHEMBL15577656

SCHEMBL15577656

O=C(O)NCc1ccno1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.41
MAPK1 P28482 2/20 0.40
TSHR P16473 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2C9 P11712 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
KCNK3 O14649 1/20 0.37
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC8A1 P32418 2/20 0.35
USP2 O75604 2/20 0.35
NTRK1 P04629 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 1/20 0.35
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488327 0.83 POLB (0.47) CTSKMAPK1CYP1A2KCNK3HCRTR1
SCHEMBL22730698 0.75 CTSK (0.43) CTSKCYP1A2
SCHEMBL17437755 0.74 HPGD (0.52) KMT2AUSP2HSD17B10POLB
SCHEMBL1588087 0.73 HPGD (0.43) TSHRSLC8A1MAPTPOLB
SCHEMBL17475553 0.73 KMT2A (0.45) TSHRCYP1A2CYP2D6CYP2C19CYP2C9
SCHEMBL13800044 0.71
SCHEMBL2574568 0.71
SCHEMBL1587102 0.70 HDAC1 (0.43) MAPK1TSHRSLC8A1
SCHEMBL9535519 0.69 SMN1; SMN2 (0.35) CTSKCYP2C9TAAR1KMT2A
SCHEMBL4789993 0.69 TSHR (0.34) TSHRCYP1A2CYP2D6CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2895482-B1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-19 EP claimed
US-9315475-B2 HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-04-19 US claimed
EP-2895482-A1 HIV PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-07-22 EP claimed
US-20140200197-A1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-07-17 US claimed
WO-2014043019-A1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-03-20 WO claimed
EP-2895482-B1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2016-10-19 EP disclosed
US-9315475-B2 HIV protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-04-19 US disclosed
US-20140200197-A1 HIV PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2014-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200197-A1 HIV PROTEASE INHIBITORS SERPINB1, PREP, PRSS1 CTSK 57/4885MAPK1 1357/4885TSHR 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.